GPCRs as potential therapeutic targets in preeclampsia
Date
2012
Authors
McGuane, J.T.
Conrad, K.P.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Drug Discovery Today: Disease Models, 2012; 9(3):e119-e127
Statement of Responsibility
J.T. McGuane, K.P. Conrad
Conference Name
Abstract
Preeclampsia is an important obstetric complication that arises in 5% of women after the 20th week of gestation, for which there is no specific therapy and no cure. Although much of the recent investigation in this field has focused on soluble forms of the angiogenic membrane receptor tyrosine kinase Flt1 and the transforming growth factor β co-receptor Endoglin, there is significant clinical potential for several GPCR targets and their agonists or antagonists in preeclampsia. In this review, we discuss several of the most promising candidates in this category, including calcitonin receptor-like receptor/receptor activity modifying protein 1 complexes, the angiotensin AT1, 2 and Mas receptors, and the relaxin receptor RXFP1. We also address some of the controversies surrounding the roles and therapeutic potential of these GPCRs and their (ant)agonists in preeclampsia.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2012 Elsevier Ltd. All rights reserved.